Insider Selling: Pharvaris (NASDAQ:PHVS) Director Sells 9,667 Shares of Stock

Pharvaris N.V. (NASDAQ:PHVS) Director Viviane Monges sold 9,667 shares of Pharvaris stock in a transaction on Thursday, May 21st. The stock was sold at an average price of $30.29, for a total transaction of $292,813.43. Following the transaction, the director directly owned 5,500 shares of the company’s stock, valued at $166,595. The trade was a 63.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Pharvaris Stock Performance

PHVS stock traded up $0.20 during mid-day trading on Tuesday, reaching $29.88. 191,721 shares of the stock traded hands, compared to its average volume of 227,155. Pharvaris N.V. has a one year low of $15.46 and a one year high of $33.33. The stock has a market capitalization of $1.95 billion, a PE ratio of -9.40 and a beta of -2.34. The business has a 50-day moving average price of $28.52 and a two-hundred day moving average price of $26.90.

Pharvaris (NASDAQ:PHVS) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.70) EPS for the quarter, topping analysts’ consensus estimates of ($0.82) by $0.12. On average, equities analysts expect that Pharvaris N.V. will post -3.25 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

PHVS has been the topic of a number of analyst reports. Wall Street Zen raised Pharvaris from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 16th. Wolfe Research started coverage on Pharvaris in a research note on Thursday, April 9th. They set an “outperform” rating and a $42.00 price target for the company. Royal Bank Of Canada dropped their price objective on Pharvaris from $52.00 to $51.00 and set an “outperform” rating for the company in a report on Monday, April 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pharvaris in a research report on Tuesday, April 21st. Finally, Wedbush increased their target price on Pharvaris from $41.00 to $42.00 and gave the stock an “outperform” rating in a research note on Tuesday, April 7th. Ten analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Pharvaris currently has a consensus rating of “Moderate Buy” and a consensus price target of $49.18.

Hedge Funds Weigh In On Pharvaris

A number of hedge funds have recently added to or reduced their stakes in the stock. California State Teachers Retirement System increased its position in shares of Pharvaris by 2.2% during the fourth quarter. California State Teachers Retirement System now owns 23,982 shares of the company’s stock worth $666,000 after acquiring an additional 520 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of Pharvaris by 30.6% in the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after purchasing an additional 783 shares during the period. GF Fund Management CO. LTD. purchased a new stake in shares of Pharvaris in the fourth quarter valued at approximately $35,000. Public Employees Retirement System of Ohio grew its stake in Pharvaris by 20.7% in the fourth quarter. Public Employees Retirement System of Ohio now owns 7,569 shares of the company’s stock worth $210,000 after purchasing an additional 1,300 shares in the last quarter. Finally, Legal & General Group Plc grew its stake in Pharvaris by 17.2% in the second quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock worth $203,000 after purchasing an additional 1,695 shares in the last quarter.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.